Goriacheva L G, Romantsov M G, Agaeva S G, Lin'kov Iu N, Kovalenko A L
Antibiot Khimioter. 2010;55(5-6):50-7.
The data on the efficacy of antivirals and their impact on the virologic and immunologic indices in HCV- and HBV-infected children are presented. The best therapeutic effect in the management of children with chronic virus hepatitis was provided by combined antiviral therapy of different action. In the treatment of babies the drugs of choice could be viferon or cycloferon, for the 2-year older children with chronic hepatitis B the combination of viferon + cycloferon should be recommended and for those with chronic hepatitis C the combination of interal + cycloferon could be used. The cycloferon combination with interferons-a makes it possible to generate the Th1 cellular immune response, to minimize the side effects of interferons and chemotherapeutics and to improve their tolerability. The complex therapy of patients with chronic hepatitis B and lambliasis, using cycloferon and macmiror, provided stable effect, less frequent relapses oflambliasis and minimum side effects of the specific therapy. The repeated isolation of lamblia within a 1-year observation period was recorded only in 16.6% of the children treated with cycloferon vs. the control (40.0%).
文中呈现了抗病毒药物的疗效数据及其对丙型肝炎病毒（HCV）和乙型肝炎病毒（HBV）感染儿童病毒学及免疫学指标的影响。不同作用机制的联合抗病毒治疗对慢性病毒性肝炎患儿的治疗效果最佳。对于婴儿，首选药物可为维福隆或环孢素；对于2岁以上的慢性乙型肝炎患儿，建议使用维福隆 + 环孢素的联合方案；对于慢性丙型肝炎患儿，可使用因他瑞 + 环孢素的联合方案。环孢素与α干扰素联合使用能够产生Th1细胞免疫反应，最大程度减少干扰素和化疗药物的副作用，并提高其耐受性。使用环孢素和马克莫罗对慢性乙型肝炎合并贾第虫病患者进行综合治疗，疗效稳定，贾第虫病复发频率降低，特异性治疗的副作用最小。在为期1年的观察期内，仅16.6%接受环孢素治疗的儿童再次检出贾第虫，而对照组这一比例为40.0%。
